Outlook Wealth Advisors LLC Boosts Stock Position in ResMed Inc. (NYSE:RMD)

Outlook Wealth Advisors LLC boosted its holdings in shares of ResMed Inc. (NYSE:RMD) by 2.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,686 shares of the medical equipment provider’s stock after acquiring an additional 102 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in ResMed were worth $900,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. OFI Invest Asset Management purchased a new stake in shares of ResMed in the 2nd quarter worth $32,000. BOK Financial Private Wealth Inc. purchased a new stake in shares of ResMed in the 1st quarter worth $35,000. Versant Capital Management Inc lifted its holdings in shares of ResMed by 196.7% in the 2nd quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 120 shares during the period. Financial Connections Group Inc. purchased a new stake in shares of ResMed in the 2nd quarter worth $37,000. Finally, Blue Trust Inc. lifted its holdings in shares of ResMed by 182.7% in the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 137 shares during the period. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $239.90, for a total transaction of $479,800.00. Following the sale, the director now owns 87,204 shares in the company, valued at approximately $20,920,239.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $239.90, for a total value of $479,800.00. Following the sale, the director now owns 87,204 shares in the company, valued at $20,920,239.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael J. Farrell sold 14,683 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $214.25, for a total value of $3,145,832.75. Following the completion of the sale, the chief executive officer now owns 440,799 shares in the company, valued at $94,441,185.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 123,874 shares of company stock worth $28,151,142. 0.71% of the stock is currently owned by insiders.

ResMed Trading Up 7.1 %

Shares of NYSE:RMD opened at $256.07 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.59 and a quick ratio of 1.69. The business’s 50-day moving average is $240.22 and its 200 day moving average is $217.35. The firm has a market capitalization of $37.58 billion, a P/E ratio of 36.95, a P/E/G ratio of 1.94 and a beta of 0.69. ResMed Inc. has a 1 year low of $132.24 and a 1 year high of $260.49.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.17. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.64 EPS. On average, research analysts predict that ResMed Inc. will post 9.08 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be paid a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 annualized dividend and a yield of 0.83%. ResMed’s payout ratio is presently 30.59%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Robert W. Baird boosted their price target on ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research report on Friday. KeyCorp boosted their price target on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research report on Friday. Bank of America boosted their price target on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. Baird R W raised ResMed to a “strong-buy” rating in a research report on Tuesday, September 24th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research report on Friday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $220.55.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.